Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.44 |
| ▸ | ACSS2 | Q9NR19 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740718 | 0.90 | ACSS2 (0.46) | GLP1RACSS2PPARGHTR7HTR6 | |
| SCHEMBL24265338 | 0.90 | ACSS2 (0.46) | GLP1RACSS2PPARGHTR7HTR6 | |
| SCHEMBL26483189 | 0.86 | GLP1R (0.45) | GLP1RACSS2PPARGAGTR1AGTR2 | |
| SCHEMBL29945993 | 0.83 | ACSS2 (0.41) | GLP1RACSS2HTR7HTR6 | |
| SCHEMBL29826815 | 0.81 | ACSS2 (0.46) | GLP1RACSS2PPARGHTR7HTR6 | |
| SCHEMBL30740795 | 0.81 | ACSS2 (0.46) | GLP1RACSS2PPARGHTR7HTR6 | |
| SCHEMBL29826194 | 0.80 | GLP1R (0.47) | GLP1RACSS2 | |
| SCHEMBL30740742 | 0.80 | GLP1R (0.47) | GLP1RACSS2 | |
| SCHEMBL26039107 | 0.79 | ACSS2 (0.43) | ACSS2BRD4 | |
| SCHEMBL22932918 | 0.79 | GLP1R (0.42) | GLP1RACSS2PPARGAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | GLP1R 1/4885ACSS2 2795/4885PPARG 365/4885 |
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | GLP1R 1/4885ACSS2 1035/4885PPARG 50/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | GLP1R 1/4885ACSS2 751/4885PPARG 27/4885 |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | GLP1R 1/4885ACSS2 1035/4885PPARG 50/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | GLP1R 1/4885ACSS2 862/4885PPARG 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.